{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:06:21Z","timestamp":1790103981327,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/gt.2017.1","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T11:21:43Z","timestamp":1486034503000},"page":"241-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Neutralizing antibodies against adeno-associated viruses in Sj\u00f6gren\u2019s patients: implications for gene therapy"],"prefix":"10.1038","volume":"24","author":[{"given":"A","family":"Corden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Handelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Cotrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Alevizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Chiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"key":"BFgt20171_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI . Sjogren's syndrome. Lancet 2005; 366: 321\u2013331.","journal-title":"Lancet"},{"key":"BFgt20171_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/01.bor.0000172801.56744.c3","volume":"17","author":"A Hansen","year":"2005","unstructured":"Hansen A, Lipsky PE, Dorner T . Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005; 17: 558\u2013565.","journal-title":"Curr Opin Rheumatol"},{"key":"BFgt20171_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00520-010-0837-6","volume":"18","author":"SB Jensen","year":"2010","unstructured":"Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010; 18: 1061\u20131079.","journal-title":"Support Care Cancer"},{"key":"BFgt20171_CR4","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1073\/pnas.0510837103","volume":"103","author":"JE Gottenberg","year":"2006","unstructured":"Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770\u20132775.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt20171_CR5","first-page":"1884","volume":"29","author":"S Tsunawaki","year":"2002","unstructured":"Tsunawaki S, Nakamura S, Ohyama Y, Sasaki M, Ikebe-Hiroki A, Hiraki A et al. Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndrome. J Rheumatol 2002; 29: 1884\u20131896.","journal-title":"J Rheumatol"},{"key":"BFgt20171_CR6","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50: 1270\u20131276.","journal-title":"Arthritis Rheum"},{"key":"BFgt20171_CR7","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1002\/art.10674","volume":"46","author":"SD Steinfeld","year":"2002","unstructured":"Steinfeld SD, Demols P, Appelboom T . Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum 2002; 46: 3301\u20133303.","journal-title":"Arthritis Rheum"},{"key":"BFgt20171_CR8","doi-asserted-by":"publisher","first-page":"19403","DOI":"10.1073\/pnas.1210662109","volume":"109","author":"BJ Baum","year":"2012","unstructured":"Baum BJ, Alevizos I, Zheng C, Cotrim AP, Liu S, McCullagh L et al. Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci USA 2012; 109: 19403\u201319407.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt20171_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/sj.gt.3302691","volume":"13","author":"H Katano","year":"2006","unstructured":"Katano H, Kok MR, Cotrim AP, Yamano S, Schmidt M, Afione S et al. Enhanced transduction of mouse salivary glands with AAV5-based vectors. Gene Ther 2006; 13: 594\u2013601.","journal-title":"Gene Ther"},{"key":"BFgt20171_CR10","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1128\/JVI.78.12.6509-6516.2004","volume":"78","author":"M Schmidt","year":"2004","unstructured":"Schmidt M, Katano H, Bossis I, Chiorini JA . Cloning and characterization of a bovine adeno-associated virus. J Virol 2004; 78: 6509\u20136516.","journal-title":"J Virol"},{"key":"BFgt20171_CR11","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1128\/JVI.02012-07","volume":"82","author":"M Schmidt","year":"2008","unstructured":"Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D, Chiorini JA . Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol 2008; 82: 1399\u20131406.","journal-title":"J Virol"},{"key":"BFgt20171_CR12","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/ibd.21673","volume":"17","author":"S van der Marel","year":"2011","unstructured":"van der Marel S, Comijn EM, Verspaget HW, van Deventer S, van den Brink GR, Petry H et al. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy. Inflamm Bowel Dis 2011; 17: 2436\u20132442.","journal-title":"Inflamm Bowel Dis"},{"key":"BFgt20171_CR13","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","volume":"101","author":"CS Manno","year":"2003","unstructured":"Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963\u20132972.","journal-title":"Blood"},{"key":"BFgt20171_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342\u2013347.","journal-title":"Nat Med"},{"key":"BFgt20171_CR15","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1128\/JVI.75.13.6199-6203.2001","volume":"75","author":"M Hildinger","year":"2001","unstructured":"Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM . Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75: 6199\u20136203.","journal-title":"J Virol"},{"key":"BFgt20171_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2005.038232","volume":"65","author":"BM Lodde","year":"2006","unstructured":"Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65: 195\u2013200.","journal-title":"Ann Rheum Dis"},{"key":"BFgt20171_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1601-0825.2011.01885.x","volume":"18","author":"JL Vosters","year":"2012","unstructured":"Vosters JL, Roescher N, Illei GG, Chiorini JA, Tak PP . TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice. Oral Dis 2012; 18: 365\u2013374.","journal-title":"Oral Dis"},{"key":"BFgt20171_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1677\/joe.1.06171","volume":"185","author":"A Voutetakis","year":"2005","unstructured":"Voutetakis A, Bossis I, Kok MR, Zhang W, Wang J, Cotrim AP et al. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J Endocrinol 2005; 185: 363\u2013372.","journal-title":"J Endocrinol"},{"key":"BFgt20171_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.virol.2006.11.032","volume":"361","author":"CD Nelson","year":"2007","unstructured":"Nelson CD, Palermo LM, Hafenstein SL, Parrish CR . Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies. Virology 2007; 361: 283\u2013293.","journal-title":"Virology"},{"key":"BFgt20171_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/jgm.678","volume":"7","author":"MR Kok","year":"2005","unstructured":"Kok MR, Voutetakis A, Yamano S, Wang J, Cotrim A, Katano H et al. Immune responses following salivary gland administration of recombinant adeno-associated virus serotype 2 vectors. J Gene Med 2005; 7: 432\u2013441.","journal-title":"J Gene Med"},{"key":"BFgt20171_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM . Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199: 381\u2013390.","journal-title":"J Infect Dis"},{"key":"BFgt20171_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/hum.2006.17.440","volume":"17","author":"CL Halbert","year":"2006","unstructured":"Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 2006; 17: 440\u2013447.","journal-title":"Hum Gene Ther"},{"key":"BFgt20171_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nri891","volume":"2","author":"DR Burton","year":"2002","unstructured":"Burton DR . Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2: 706\u2013713.","journal-title":"Nat Rev Immunol"},{"key":"BFgt20171_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1477-7525-7-46","volume":"7","author":"B Segal","year":"2009","unstructured":"Segal B, Bowman SJ, Fox PC, Vivino FB, Murukutla N, Brodscholl J et al. Primary Sjogren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009; 7: 46.","journal-title":"Health Qual Life Outcomes"},{"key":"BFgt20171_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/labinvest.2010.164","volume":"91","author":"CQ Nguyen","year":"2011","unstructured":"Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB . IL17: potential therapeutic target in Sjogren's syndrome using adenovirus-mediated gene transfer. Lab Invest 2011; 91: 54\u201362.","journal-title":"Lab Invest"},{"key":"BFgt20171_CR26","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1186\/ar3753","volume":"14","author":"H Yin","year":"2012","unstructured":"Yin H, Nguyen CQ, Samuni Y, Uede T, Peck AB, Chiorini JA . Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL\/6.NOD-Aec1Aec2 mouse model of Sjogren's syndrome. Arthritis Res Ther 2012; 14: R40.","journal-title":"Arthritis Res Ther"},{"key":"BFgt20171_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2144\/02331dd04","volume":"33","author":"RH Smith","year":"2002","unstructured":"Smith RH, Afione SA, Kotin RM . Transposase-mediated construction of an integrated adeno-associated virus type 5 helper plasmid. Biotechniques 2002; 33: 204\u2013206; 8, 10-1.","journal-title":"Biotechniques"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt20171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt20171","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt20171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:21:51Z","timestamp":1648560111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt20171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFgt20171"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.1","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]},"assertion":[{"value":"18 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}